Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug;190(3):e141-e143.
doi: 10.1111/bjh.16916. Epub 2020 Jun 28.

Terminal complement inhibition dampens the inflammation during COVID-19

Austin G Kulasekararaj  1   2   3 , Ioanna Lazana  1 , Joanna Large  1 , Kristina Posadas  2 , Helen Eagleton  4 , John Lord Villajin  2 , Mark Zuckerman  5 , Shreyans Gandhi  1   2 , Judith C W Marsh  1   3
Affiliations

Terminal complement inhibition dampens the inflammation during COVID-19

Austin G Kulasekararaj et al. Br J Haematol. 2020 Aug.
No abstract available

Keywords: C5 inhibition; COVID-19; complement activation; paroxysmal nocturnal haemoglobinuria.

PubMed Disclaimer

References

    1. Gralinski LE, Sheahan TP, Morrison TE, Menachery VD, Jensen K, Leist SR, et al. Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. MBio. 2018;9(5): e01753‐18. - PMC - PubMed
    1. Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333(19):1253–8. - PubMed
    1. Hillmen P, Hall C, Marsh JCW, Elebute M, Bombara MP, Petro BE, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2004;350(6):552–9. - PubMed
    1. Kulasekararaj AG, Hill A, Rottinghaus ST, Langemeijer S, Wells R, Gonzalez‐Fernandez FA, et al. Ravulizumab (ALXN1210) vs eculizumab in C5‐inhibitor‐experienced adult patients with PNH: the 302 study. Blood. 2019;133(6):540–9. - PMC - PubMed
    1. Risitano AM, Mastellos DC, Huber‐Lang M, Yancopoulou D, Garlanda C, Ciceri F, et al. Complement as a target in COVID‐19? Nat Rev Immunol. 2020;20(6):343–4. - PMC - PubMed

MeSH terms

Substances